赛马鲁肽
医学
心力衰竭
肥胖
内科学
物理疗法
减肥
安慰剂
心脏病学
2型糖尿病
糖尿病
内分泌学
替代医学
病理
利拉鲁肽
作者
Ambarish Pandey,Dalane W Kitzman,Khaja Chinnakondepalli,Shachi Patel,Barry A Borlaug,Javed Butler,Melanie J. Davies,Sanjiv J. Shah,Subodh Verma,Cecilia Rönnbäck,A. Domdey,Karoline Liisberg,Morten Schou,Eduardo Perna,Fozia Ahmed,Michael Fu,Mark C. Petrie,Mikhail Kosiborod
标识
DOI：10.1016/j.jchf.2025.102610
摘要
Semaglutide resulted in a similar reduction in BW across frailty subgroups but greater improvements in HF-related symptoms. Moreover, semaglutide reduced frailty burden after 52 weeks of treatment. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511) (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM]; NCT04916470).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
BowieHuang
浮游
shhoing
皮皮
JiahaoRao
无极微光
Linos
eric888
GingerF
tianzml0
含糊的尔槐
gexzygg
黑翅鸢
Criminology34
七慕凉
aldehyde
小青椒
发文章
blackddl
nPgA2o
子车茗
null
hbit
裂冰
皖公网安备34019202002308
